Literature DB >> 30092355

The functional pathway analysis and clinical significance of miR-20a and its related lncRNAs in breast cancer.

Luqing Zhao1, Yuelong Zhao2, Yanong He2, Qingling Li1, Yitao Mao3.   

Abstract

BACKGROUND: miR-20a is a critical molecule in various biological processes and cancer progression procedures. However, its relationships with lncRNAs and their functional pathway analysis in breast tumorigenesis are less intensively studied.
METHODS: The expression data from TCGA database and multiple bioinformatics resources were used to check the expression levels, survival curves, interactions and functional illustrations of miR-20a and its related lncRNAs (XIST, H19 and MALAT1) in breast cancer patients. The luciferase reporter assays and Pearson's correlation analyses were utilized to verify the direct regulatory relationship between miR-20a and three lncRNAs (XIST, H19 and MALAT1). In vitro cell proliferation, migration and invasion assays, were performed to check the biological effects of miR-20a and XIST in different breast cancer cell lines. The receiver operating characteristic curve (ROC) analyses were done for evaluating diagnostic values of serum miR-20a and XIST in breast cancer patients.
RESULTS: The miR-20a expression was significantly up-regulated in both breast cancer samples and serum samples, and correlated with poor survival rate in breast cancer patients. LncRNAs (XIST, H19 and MALAT1) directly bound to hsa-miR-20a and were negatively correlated with hsa-miR-20a expression in breast cancer patient samples. For functional illustrations and downstream signaling pathways analysis, XIST, H19 and MALAT1 mainly shared their regulatory functions in cell motility and interleukin signaling in breast cancer progression. Additionally, over-expression of miR-20a and inhibition of XIST promoted breast cancer cell growth, migration and invasion in vitro, and serum miR-20a and XIST served as potential diagnostic biomarkers for breast cancer with the area under ROC curve (AUC) of 0.87 (95% CI = 0.78 to 0.97), and 0.78 (95% CI = 0.67 to 0.89) respectively.
CONCLUSIONS: Taken together, these findings provide us novel insights and avenues for utilizing miR-20a and its related lncRNAs as potential diagnostic biomarkers and promising therapeutic targets for breast cancer treatment.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Interaction; Pathway analysis; lncRNAs; miR-20a

Mesh:

Substances:

Year:  2018        PMID: 30092355     DOI: 10.1016/j.cellsig.2018.08.004

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  6 in total

1.  LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.

Authors:  Chengjun Sui; Zhitao Dong; Cheng Yang; Minfeng Zhang; Binghua Dai; Li Geng; Jiongjiong Lu; Jiamei Yang; Minhui Xu
Journal:  J Cell Mol Med       Date:  2019-06-18       Impact factor: 5.310

Review 2.  Emerging Roles and Mechanisms of lncRNA FOXD3-AS1 in Human Diseases.

Authors:  Qinfan Yao; Xiuyuan Zhang; Dajin Chen
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

3.  Identification of multi-omics biomarkers and construction of the novel prognostic model for hepatocellular carcinoma.

Authors:  Xiao Liu; Chiying Xiao; Kunyan Yue; Min Chen; Hang Zhou; Xiaokai Yan
Journal:  Sci Rep       Date:  2022-07-15       Impact factor: 4.996

Review 4.  X-Inactive-Specific Transcript: Review of Its Functions in the Carcinogenesis.

Authors:  Soudeh Ghafouri-Fard; Sepideh Dashti; Molood Farsi; Mohammad Taheri; Seyed Ali Mousavinejad
Journal:  Front Cell Dev Biol       Date:  2021-06-11

Review 5.  Biological Function of Long Non-coding RNA (LncRNA) Xist.

Authors:  Wenlun Wang; Lu Min; Xinyuan Qiu; Xiaomin Wu; Chuanyang Liu; Jiaxin Ma; Dongyi Zhang; Lingyun Zhu
Journal:  Front Cell Dev Biol       Date:  2021-06-10

6.  Long Noncoding RNA Serve as a Potential Predictive Biomarker for Breast Cancer: A Meta-Analysis.

Authors:  Xuefeng Jiang; Guijuan Zhang; Jieyan Wu; Shujun Lin; Yusheng Liu; Yi Ma; Min Ma
Journal:  Biomed Res Int       Date:  2020-05-10       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.